Skip to content
Contact Us
Webinar - On Demand

Illuminating Immunohistochemistry: From Biomarker to Clinical Trial Assay

Date: July 24, 2024

Duration: 60 Minutes

This on-demand session provides a foundational overview of IHC, starting from its preclinical applications and extending to its pivotal role in early clinical trials. Our expert speakers, Amanda Woodrooffe, PhD, providing a scientific perspective, and Dawn Butler, MD, offering insights from a pathologist’s viewpoint, guide you through the essential aspects of IHC, including its importance in biomarker validation and the transition from preclinical assay development to early clinical application.
 
In this webinar, we discuss in detail the complex process of antibody selection, covering both commercial and proprietary types. You’ll learn about the benefits of using IHC for target and biomarker validation, and understand its multifaceted applications in disease screening and decision-making for treatment.


Topics covered:

  • Fundamentals of IHC and its role in preclinical and early clinical trials.
    Detailed exploration of the IHC biomarker identification and validation processes.
     
  • Guidance on transitioning IHC assays from research to early clinical practice.
     
  • How IHC compares to other tissue profiling technologies including PCR, NGS, and multiplex immunofluorescence.
     
  • The importance of antibody selection, guidance on selection criteria for antibodies, and how to apply this in assay development.

Register to Watch Webinar On Demand
Speakers

Amanda Woodroofe

Amanda Woodrooffe, PhD
Precision for Medicine

Amanda Woodrooffe, PhD, is the head of  Precision for Medicine's UK labs. She brings years of experience as a leader of scientific operations and excels as a collaborative partner. She focuses on methods and approaches to provide actionable data which can directly enable biopharmaceutical research and development.

Dawn Butler

Dawn Butler, MD
Precision for Medicine

Dr. Butler, a triple-board certified pathologist specializing in hematopathology, has a clinical diagnostic medicine background. She has six years of experience in IHC validation with the industry. Currently, she collaborates with clients to validate immunohistochemistry for clinical trial patient enrollment.